TBPH Earnings Theravance Biopharma, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–27 of 27
| Q2 2026 | 2026-06-30 | -0.21 | 2026-08-11 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.10 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | 2.06 | 2026-03-23 | 10-K |
| FY 2025 | 2025-09-30 | 0.07 | 2026-03-23 | 10-K |
| Q2 2026 | 2025-06-30 | 0.81 | 2026-08-11 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.27 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.15 | 2026-03-23 | 10-K |
| FY 2025 | 2024-09-30 | -0.26 | 2026-03-23 | 10-K |
| FY 2025 | 2024-06-30 | -0.34 | 2026-03-23 | 10-K |
| FY 2025 | 2024-03-31 | -0.24 | 2026-03-23 | 10-K |
| FY 2024 | 2023-12-31 | -1.00 | 2025-03-07 | 10-K |
| FY 2024 | 2023-09-30 | -0.17 | 2025-03-07 | 10-K |
| FY 2024 | 2023-06-30 | -0.28 | 2025-03-07 | 10-K |
| FY 2024 | 2023-03-31 | -0.35 | 2025-03-07 | 10-K |
| FY 2023 | 2022-12-31 | 11.85 | 2024-03-01 | 10-K |
| FY 2023 | 2022-09-30 | 12.14 | 2024-03-01 | 10-K |
| FY 2023 | 2022-06-30 | -0.11 | 2024-03-01 | 10-K |
| FY 2023 | 2022-03-31 | -0.34 | 2024-03-01 | 10-K |
| FY 2022 | 2021-12-31 | -2.87 | 2023-03-01 | 10-K |
| FY 2022 | 2021-09-30 | -0.48 | 2023-03-01 | 10-K |
| FY 2022 | 2021-06-30 | -0.80 | 2023-03-01 | 10-K |
| FY 2022 | 2021-03-31 | -1.24 | 2023-03-01 | 10-K |
| FY 2022 | 2020-12-31 | -4.46 | 2023-03-01 | 10-K |
| FY 2021 | 2020-09-30 | -1.16 | 2022-02-28 | 10-K |
| FY 2021 | 2020-06-30 | -1.00 | 2022-02-28 | 10-K |
| FY 2021 | 2020-03-31 | -1.40 | 2022-02-28 | 10-K |
| FY 2021 | 2019-12-31 | -4.25 | 2022-02-28 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.